Table 6.
Incidence of grade ≥ 3 treatment-emergent adverse events related to study treatment occurring in ≥ 10% of the pediatric patients receiving recommended dosage (MT103-205)
| Preferred term | Patients, n (%) N = 70 (5/15 µg/m2/day) |
|---|---|
| Any | 61 (87) |
| Anemia | 25 (36) |
| Thrombocytopenia | 15 (21) |
| Febrile neutropenia | 12 (17) |
| Hypokalemia | 12 (17) |
| Neutropenia | 12 (17) |
| Alanine aminotransferase increased | 11 (16) |
| Platelet count decreased | 10 (14) |
| Pyrexia | 10 (14) |
| Neutrophil count decreased | 9 (13) |
| Aspartate aminotransferase increased | 8 (11) |
| Leukopenia | 7 (10) |
| White blood cell count decreased | 7 (10) |
von Stackelberg et al. [24]